When Gary Glick, Ph.D., left the CEO post at IFM Therapeutics, he didn’t know what was next. But he soon found himself on a plane with Loxo Oncology co-founder Keith Flaherty, and they got to talking about how they could “expand the boundaries of targeted oncology.” Scorpion Therapeutics was born.
![](https://qtxasset.com/styles/breakpoint_sm_default_480px_w/s3/fiercebiotech/1586349438/Arrakis%20management%20April%202020.jpg?uZNTLVMDrKjiozmlo1QMQEM8isYqufDO&itok=lw6lrLrr)
Arrakis Therapeutics has been dodging pharma suitors since its early days, keeping its head down, building its RNA-targeting technology and “politely declining” advances “because we weren’t ready.”